Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease

Lung

Volumn 196, Issue 4, 2018, Pages 409-416

  Mango, Robert L ^a   Matteson, Eric L ^a   Crowson, Cynthia S ^a   Ryu, Jay H ^a   Makol, Ashima ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Interstitial lung disease; Mortality modeling; Non specific interstitial pneumonia; Systemic sclerosis; Usual interstitial pneumonia

Indexed keywords

ANTINUCLEAR ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; AGE; AGED; ARTICLE; CALIBRATION; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; STANDARDIZED MORTALITY RATIO; SURVIVAL TIME; SYSTEMIC SCLEROSIS; COMPARATIVE STUDY; EPIDEMIOLOGY; LUNG; MIDDLE AGED; MINNESOTA; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SEX FACTOR; TERTIARY CARE CENTER; TIME FACTOR;

AGE FACTORS; AGED; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MINNESOTA; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEX FACTORS; SMOKING; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 85047193899     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-018-0126-6     Document Type: Article

References (31)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y (2012) Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 51(6):1017–1026. 10.1093/rheumatology/ker269
2. Bauer PR, Schiavo DN, Osborn TG, Levin DL, St Sauver J, Hanson AC, Schroeder DR, Ryu JH (2013) Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 144(2):571–577. 10.1378/chest.12-2768
3. D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46(3):428–440
4. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691. 10.7326/0003-4819-156-10-201205150-00004
5. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, Collard HR (2014) Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145(4):723–728. 10.1378/chest.13-1474
6. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167(7):962–969. 10.1164/rccm.2111053
7. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(4):459–466. 10.1164/rccm.201011-1790OC
8. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr (2014) 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43(5):1421–1429. 10.1183/09031936.00131813
9. Ryerson CJ, O’Connor D, Dunne JV, Schooley F, Hague CJ, Murphy D, Leipsic J, Wilcox PG (2015) Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 148(5):1268–1275. 10.1378/chest.15-0003
10. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL (2017) Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology 56(3):344–350. 10.1093/rheumatology/kew391
11. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE Jr, Collard HR, Lee JS (2017) Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model. Chest. 10.1016/j.chest.2017.06.009
12. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 (2002). Am J Respir Crit Care Med 165 (2):277–304. 10.1164/ajrccm.165.2.ats01
13. Crowson CS, Atkinson EJ, Therneau TM (2016) Assessing calibration of prognostic risk scores. Stat Methods Med Res 25(4):1692–1706. 10.1177/0962280213497434
14. Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23(13):2109–2123. 10.1002/sim.1802
15. Travis WD, Matsui K, Moss J, Ferrans VJ (2000) Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 24(1):19–33
16. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP, Martinez FJ (2003) Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58(2):143–148
17. Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, Curran-Everett D, Gillis JZ, Meehan RT, Brown KK (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134(3):601–605. 10.1378/chest.08-0053
18. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 10.1016/s2213-2600(16)30152-7
19. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666. 10.1056/NEJMoa055120
20. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM (2017) Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheum (Hoboken, NJ) 69 (7):1451–1460. 10.1002/art.40114
21. Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU (2008) Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 177(2):190–194. 10.1164/rccm.200612-1759OC
22. Hissaria P, Roberts-Thomson PJ, Lester S, Ahern MJ, Smith MD, Walker JG (2011) Cigarette smoking in patients with systemic sclerosis reduces overall survival: comment on the article by Hudson et al. Arthritis Rheum 63(6):1758–1759. 10.1002/art.30352
23. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769. 10.1016/s0140-6736(11)60405-4
24. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T (2011) The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12:93. 10.1186/1465-9921-12-93
25. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1(5):369–376. 10.1016/s2213-2600(13)70105-x
26. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR (2014) Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 108(7):1023–1030. 10.1016/j.rmed.2014.04.011
27. Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V (2015) Connective tissue disease-associated interstitial lung diseases (CTD-ILD)—report from OMERACT CTD-ILD Working Group. J Rheumatol 42(11):2168–2171. 10.3899/jrheum.141182
28. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU (Hoboken (2017) Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 69(8):1670–1678. 10.1002/art.40130
29. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254. 10.1164/rccm.200706-877OC
30. Al-Dhaher FF, Pope JE, Ouimet JM (2010) Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 39(4):269–277. 10.1016/j.semarthrit.2008.06.002
31. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581–1586. 10.1164/rccm.2106012